Gradientech responds to call for new diagnostic approaches to combat antimicrobial resistance at AMR Conference in Berlin

Uppsala, Sweden, March 18, 2019. Speaking at the Novel Antimicrobials and AMR Diagnostics Conference in Berlin, Gradientech, developer of the QuickMIC™ rapid IVD system for antibiotic susceptibility testing (AST), stressed the importance of adopting new diagnostic approaches in the fight against antimicrobial resistance.

Antibiotic resistance is one of the biggest threats to global health today. lts impact is perhaps seen most clearly in the continuing rise in deaths from infections due to bacteria resistant to antibiotics -- at least 33,000 annually in Europe alone.

"The World Health Organization has already called for a new generation of rapid

microbiology tests to determine which antibiotics an infected patient should be treated with to reduce misuse and overuse of antibiotics and limit the spread of resistance," says Sara Thorslund, CEO of Gradientech. "We foresee that our IVD QuickMIC system, which is in final development, will make areal difference by diagnosing bacterial resistance in patients with suspected sepsis in as short as 2 hours based on bacterial growth."

At the AMR conference, Gradientech was participating in a special session on diagnostics chaired by Dr Till Bachmann from the University of Edinburgh, and member of the JPIAMR (Joint Programming lnitiative on Antimicrobial Resistance) SAB, who added: "Reducing over and inappropriate use of antibiotics remains a major challenge. New diagnostic approaches are urgently required, and I welcome the initiatives of companies such as Gradientech and the other panellists here in Berlin."

For further information, please contact:
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se

About Gradientech
Gradientech is a diagnostics company developing the in vitro diagnostic QuickMIC® system, a new platform for antibiotic susceptibility testing based on phenotypic bacterial growth analysis. The system is expected to become the most rapid solution for determining appropriate antibiotic treatment of sepsis patients. Rapid antibiotic susceptibility testing is vital for increasing sepsis patient survival, reducing healthcare costs and lowering the spread of antibiotic resistance. www.gradientech.se

Subscribe

Media

Media